The Medicines Co. CEO Timney On Selling Inclisiran And Why Big Pharma Is Still Interested In CV Disease

Mark Timney took over the helm at The Medicines Company in December with a singular focus: wrapping up the Phase III program for inclisiran and finding a buyer for the cholesterol-lowering drug. 

The Medicines Company Mark Timney

The Medicines Co.'s new CEO Mark Timney took over the helm in December to execute a straightforward business plan: shepherd the RNAi therapeutic inclisiran successfully through Phase III development and find a buyer for the cholesterol lowering medicine.

"There is no doubt in my mind to really fulfill its full potential, [inclisiran] is better off in the hands...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category